Mohieldin M. Youssef 

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Sorafenib (SOR) is the first-line treatment for hepatocellular carcinoma (HCC). However, its use is hindered by the recently expressed safety concerns. One approach for reducing SOR toxicity is to use lower doses in combination with other less toxic agents. Biochanin-A (Bio-A), a promising isoflavone, showed selective toxicity to liver cancer cells. We(More)
  • 1